Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors
RATIONALE: Epoetin beta may cause the body to make more red blood cells and may help relieve fatigue in patients with malignant solid tumors receiving palliative care.
PURPOSE: This phase II trial is studying how well epoetin beta works in treating fatigue and anemia in patients receiving palliative care for malignant solid tumors.
Unspecified Adult Solid Tumor, Protocol Specific
Biological: epoetin beta
Procedure: quality-of-life assessment
|Study Design:||Allocation: Non-Randomized
Primary Purpose: Supportive Care
|Official Title:||Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor|
- Quality of life
- Hemoglobin level
|Study Start Date:||November 2005|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
- Evaluate the impact of epoetin beta on fatigue and quality of life of patients receiving palliative care for malignant solid tumors.
- Evaluate the impact of epoetin beta on hemoglobin level (increase > 2 g/dL).
OUTLINE: Patients receive epoetin beta subcutaneously once a week for up to 3 months.
Fatigue, quality of life, and hemoglobin and reticulocyte levels are assessed every 4 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00559195
|Centre Hospital Regional Universitaire de Limoges|
|Limoges, France, 87042|
|Study Chair:||Jean-Luc Labourey||Centre Hospital Regional Universitaire de Limoges|